Fig 1.
Flowchart of Study Selection.
Table 1.
Studies Included in Meta-Analysis.
Table 2.
Clinical Characteristics of Included Studies.
Fig 2.
Forest plots of HR for recurrence with SUVmax (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).
The Chi2 test is a measurement of heterogeneity. P<0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95% CI. Fixed: fixed effect model. Random: random effect model.
Fig 3.
Funnel plots without (left column) and with (right column) trim and fill.
The pseudo 95% confidence interval (CI) is computed as part of the analysis that produced the funnel plot and corresponds to the expected 95% CI for a given standard error (SE). HR indicates hazard ratio.
Fig 4.
Forest plots of HR for deaths with SUVmax (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).
The Chi2 test is a measurement of heterogeneity. P<0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95%CI. Fixed: fixed effect model. Random: random effect model.
Table 3.
Total and subgroup analyses of SUVmax, MTV and TLG in surgical NSCLC.
Table 4.
Previous meta-analyses of 18F-FDG PET/CT on survival of NSCLC patients.